This Month
June 2009
Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30
Year Archive
Login
User name:
Password:
Remember me 
Contact Information:

For More Information Contact: Rimon Therapeutics Limited 59 Adelaide St. East Suite 500 Toronto, Ontario Canada, M5C 1K6, 416-977-2003 (office), 416-977-6383 (fax), info@rimontherapeutics.com (email) or visit our website at: www.rimontherapeutics.com

Media Contact: Howard Oliver, What If What Next, 416-638-8582, holiver@whatifwhatnext.com.

 

Coverage of Rimon Therapeutics in Exchange

Revolutionary wound dressing will kick-start healing

When you cut your skin, the wound starts to repair itself almost immediately. But for chronic wounds the body needs more than a bandage to allow this healing process to begin.

In North America, millions of chronic wounds require constant care amounting to over $20 billion annually.

Toronto-based Rimon Therapeutics Ltd. has developed a “smart” dressing made from advanced medical polymers (plastics) that supports the body's natural healing process.

Rimon's MI-Sorb is an easy-to-apply dressing that contains the company's revolutionary bioactive materials called Theramers.

“Theramers allows the body to heal without the side effects or costs of conventional drugs,” said Michael May, President of Rimon.

The MI-Sorb dressing works by removing the tissue-destroying enzymes in chronic wounds (like diabetic ulcers or bedsores), kick-starting the natural healing process.

Developed from research at the University of Toronto, Rimon received its initial funding from Ontario Centres of Excellence (OCE) when co-founder Michael May was named the 1997 recipient of OCE's Martin Walmsley Fellowship for Technological Entrepreneurship.

OCE also worked to connect Rimon with world-class researchers, assisted with staff hiring and allowed the company to explore new technologies for licensing.

The first clinical trials of the MI-Sorb dressing have been completed, and Rimon plans to bring its product to market soon through a partnership with an established wound-care company. Future therapeutic applications include treating heart disease, delaying knee replacement and preventing medical device related infections.

For more see: http://www.exchangemagazine.com/morningpost/2009/week26/Tuesday/062311.htm
Posted to: 
No comments found.
Trackbacks

TrackBack URL:
http://rimon.blogware.com/blog/_trackback/4234442

No trackbacks found.
Post comment:
Format Type: 
  Convert newlines
  Receive comment notifications for this article
Subject: 
   
insert bold tags insert italic tags insert underline tags insert strikethough tags insert link insert blockquote tags
Comment: 
Comment verification:

Please enter the text you see inside the graphic to post your comment:
This blog does not allow anonymous comments. Please provide your username and password along with your comment.
Login information:
Username: 
Password: 
If you would like to post contact information on your comment, please enter your information into the optional fields below:
Contact information:
URL:  example: http://yourdomain.com